Amgen/J&J Procrit arbitration
Executive Summary
Johnson & Johnson will retain license to sell Procrit (epoetin alfa) in the U.S. following Oct. 18 decision by an arbitration panel, but will pay Amgen $150 mil. in damages. J&J is seeking attorneys' fees. Amgen argued that J&J intentionally sold Procrit in Amgen's exclusive dialysis market, violating a 1985 agreement between the companies. Amgen sells epoetin alfa as Epogen for dialysis patients, while J&J sells Procrit in non-dialysis markets (1"The Pink Sheet" March 20, 2000, p. 19)...
You may also be interested in...
Amgen Effort To Reclaim Procrit Rights From J&J Moving To Trial Phase
Amgen will receive a trial in its arbitration claim seeking to terminate Johnson & Johnson's license to sell Procrit in the U.S., but appears to have a difficult burden to meet before the arbitration panel.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.